Novavax, Inc. (NASDAQ:NVAX) Shares Sold by Commonwealth Equity Services LLC

Commonwealth Equity Services LLC lowered its position in Novavax, Inc. (NASDAQ:NVAX) by 32.8% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 43,437 shares of the biopharmaceutical company’s stock after selling 21,182 shares during the quarter. Commonwealth Equity Services LLC’s holdings in Novavax were worth $550,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Swedbank AB acquired a new stake in Novavax in the 1st quarter valued at approximately $26,000. Signaturefd LLC grew its stake in shares of Novavax by 214.5% in the second quarter. Signaturefd LLC now owns 5,680 shares of the biopharmaceutical company’s stock worth $72,000 after purchasing an additional 3,874 shares in the last quarter. Herr Investment Group LLC acquired a new position in shares of Novavax during the first quarter valued at $48,000. Alpine Global Management LLC bought a new stake in shares of Novavax during the first quarter valued at about $49,000. Finally, Ameritas Investment Partners Inc. lifted its holdings in Novavax by 31.6% in the first quarter. Ameritas Investment Partners Inc. now owns 11,298 shares of the biopharmaceutical company’s stock worth $54,000 after purchasing an additional 2,711 shares during the period. Institutional investors own 53.04% of the company’s stock.

Novavax Trading Up 3.1 %

NASDAQ:NVAX opened at $12.91 on Friday. The company has a 50-day moving average of $13.01 and a 200-day moving average of $10.66. The firm has a market cap of $1.81 billion, a price-to-earnings ratio of -4.07 and a beta of 2.04. Novavax, Inc. has a twelve month low of $3.53 and a twelve month high of $23.86.

Novavax (NASDAQ:NVAX) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported $0.99 earnings per share for the quarter, missing analysts’ consensus estimates of $1.82 by ($0.83). The company had revenue of $415.50 million for the quarter, compared to analysts’ expectations of $458.57 million. The business’s quarterly revenue was down 2.1% compared to the same quarter last year. During the same period last year, the firm earned $0.58 EPS. On average, research analysts forecast that Novavax, Inc. will post -1.04 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have commented on NVAX shares. JPMorgan Chase & Co. raised their target price on shares of Novavax from $8.00 to $9.00 and gave the company an “underweight” rating in a research note on Monday, August 12th. B. Riley reiterated a “buy” rating and set a $23.00 price objective (down previously from $25.00) on shares of Novavax in a research note on Monday, August 12th. Finally, Bank of America upped their target price on Novavax from $12.00 to $18.00 and gave the stock a “neutral” rating in a research report on Friday, June 14th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, Novavax has an average rating of “Hold” and a consensus target price of $15.80.

Novavax Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.